Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session

1O - Furmonertinib versus gefitinib in treatment-naïve EGFR mutated non-small cell lung cancer: a randomized, double-blind, multi-center, phase III study (FURLONG)


31 Mar 2022


Proffered Paper session


Targeted Therapy

Tumour Site

Non-Small Cell Lung Cancer


Yuan-Kai Shi


Annals of Oncology (2022) 33 (suppl_2): S27-S70. 10.1016/annonc/annonc856


Y. Shi1, G. Chen2, X. Wang3, Y. Liu4, L. Wu5, Y. Hao6, C. Liu7, S. Zhu8, X. Zhang9, Y. Li10, J. Liu11, L. Cao12, Y. Cheng13, H. Zhao14, S. Zhang15, A. Zang16, J. Cui17, J. Feng18, F. Liu19, C. Gu19

Author affiliations

  • 1 Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center and National Clinical Research Center for Cancer and Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing/CN
  • 2 Harbin Medical University Cancer Hospital, Harbin/CN
  • 3 Xuzhou Central Hospital, Xuzhou/CN
  • 4 The First Hospital of China Medical University, Shenyang/CN
  • 5 Hunan Cancer Hospital (The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University), Changsha/CN
  • 6 The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning/CN
  • 7 Cancer Hospital of Xinjiang Medical University, Urumqi/CN
  • 8 The Affiliated Hospital of Xuzhou Medical College, Xuzhou/CN
  • 9 Nantong Cancer Hospital, Nantong/CN
  • 10 The First Affiliated Hospital of Wenzhou Medical University, Wenzhou/CN
  • 11 The First Affiliated Hospital of Dalian Medical University, Dalian/CN
  • 12 Anhui Provincial Hospital, The First Affiliated Hospital of the University of Science and Technology of China, Anhui Provincial Hospital, Hefei/CN
  • 13 Jilin Cancer Hospital, Changchun/CN
  • 14 The Second Hospital of Anhui University, Hefei/CN
  • 15 Beijing Chest Hospital, Beijing/CN
  • 16 Affiliated Hospital of Hebei University, 71000 - Baoding/CN
  • 17 The First Hospital of Jilin University, Changchun/CN
  • 18 Affiliated Hospital of Nantong University, Nantong/CN
  • 19 Shanghai Allist Pharmaceutical Technology, Shanghai/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1O


Furmonertinib (AST2818) is an irreversible, selective third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). This study aimed to compare the efficacy and safety of furmonertinib versus gefitinib in untreated advanced non-small cell lung cancer (NSCLC) patients with EGFR sensitizing mutations.


FURLONG was a randomized, double-blind, phase III study conducted in 55 centers across mainland China. Stage IIIB/IIIC/IV NSCLC patients with EGFR Ex19Del or L858R mutation positive were enrolled to receive either furmonertinib 80 mg/d or gefitinib 250 mg/d as first-line therapy. The primary endpoint was progression-free survival (PFS) assessed by an independent review center (IRC).


Between May 30, 2019 and Dec 5, 2019, 358 patients were randomized to receive furmonertinib (n=178) or gefitinib (n=180) treatment. In the furmonertinib and gefitinib groups, 35% and 32% had central nervous system (CNS) metastases at baseline, respectively. As of Sep 15 2021, the median follow-up was both 21.0 months in each group. The median PFS with furmonertinib was significantly longer than with gefitinib (20.8 versus 11.1 months; HR 0.44 [95%CI 0.34-0.58]; p<0.0001). The clinical benefit of PFS was consistent across all pre-specified subgroups including patients with CNS metastases (HR 0.50 [95%CI 0.32-0.80]). The median duration of exposure was 18.3 months in the furmonertinib group and 11.2 months in the gefitinib group, whereas the frequency of grade≥3 treatment-related adverse events (TRAEs) was 11% in the furmonertinib group and 18% in the gefitinib group.


Furmonertinib significantly prolonged PFS and showed less grade≥3 TRAEs compared with gefitinib as first-line treatment in advanced EGFR mutated NSCLC patients.

Clinical trial identification

NCT03787992; First posted on Dec 27, 2018.

Legal entity responsible for the study

Shanghai Allist Pharmaceutical Technology.


Shanghai Allist Pharmaceutical Technology; China National Major Project for New Drug Innovation (2017ZX09304015).


F. Liu, C. Gu: Financial Interests, Personal, Full or part-time Employment: Shanghai Allist Pharmaceutical Technology; Financial Interests, Personal, Stocks/Shares: Shanghai Allist Pharmaceutical Technology. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.